NYSE:BSX News 22 October 2025 - 19 December 2025

Boston Scientific Corporation (NYSE: BSX) stock is trading lower in Friday’s session, with shares at $95.76 as of 17:30 UTC on December 19, 2025 (down 0.36% on the day). The stock’s intraday range has run from $95.64 to $97.24, after opening at $96.85 on volume of roughly 4.49 million shares at the time of this update. The move comes one day after BSX closed at $96.11 on Thursday, December 18, extending a three-session winning streak and drawing heavier-than-usual trading activity. MarketWatch reported Thursday’s volume near 15.6 million shares, above a 50‑day average around 9.0 million, while noting the stock remained

Boston Scientific Corporation (NYSE: BSX) finished Thursday’s session (December 18, 2025) on a strong note, and early after-hours trading was notably calm—an important tell for investors heading into Friday’s open (December 19). Shares closed at $96.11, up 1.73%, marking a third straight daily gain in a broadly higher market session. MarketWatch Below is a roundup of what moved BSX today, what Wall Street forecasts look like after fresh analyst updates, and the practical “before-the-bell” checklist for Friday. BSX stock after the bell: the Thursday, Dec. 18 recap Regular session (4:00 p.m. ET close): After-hours (as of 6:00 p.m. ET): That

Boston Scientific Corporation (NYSE: BSX) ended Wednesday, December 17, 2025, in positive territory even as the broader market sold off. The medical-device maker’s shares closed up 1.65% at $94.48, extending gains for a second session and outperforming several large medtech peers in a risk-off tape. MarketWatch In after-hours trading, BSX ticked modestly higher, a sign that investors largely digested the day’s analyst updates and macro crosscurrents without a major change in sentiment. Here’s what stood out after the bell — and what investors will likely be watching before the U.S. market opens Thursday, December 18, 2025. BSX price action after

Boston Scientific Corporation (NYSE: BSX) is back in the spotlight on Wednesday, December 17, 2025, as fresh Wall Street commentary and a new round of target-price updates reframe the conversation around the medtech leader’s 2026 setup—especially in fast-growing cardiac categories like electrophysiology (EP) and left atrial appendage closure (WATCHMAN). Investing.com+1 While Boston Scientific shares have been under pressure recently—down nearly 10% over the past month according to UBS—today’s headlines tilt toward a familiar theme: analysts see the pullback as creating a more attractive entry point into a multi-year growth story, even as valuation and policy risks remain key watch items.

Boston Scientific Corporation (NYSE: BSX) is back in the spotlight on Tuesday, December 16, 2025, as the stock trades in the low-$90s—well below its September highs—while Wall Street’s broader view remains notably upbeat on the medical-device leader’s growth outlook. As of the latest available market data, BSX traded around $92.23 on Dec. 16, with an intraday range of roughly $90.44 to $92.77. That places the stock about 16% below its 52‑week high of $109.50 and roughly 7% above its 52‑week low of $85.98, highlighting how sharply sentiment has cooled since the late-summer peak even as fundamentals have stayed resilient. MarketBeat

Boston Scientific Corporation (NYSE: BSX) heads into Wednesday’s U.S. trading session looking bruised but far from broken. On Tuesday, December 9, 2025, Boston Scientific stock slipped about 1.4% to roughly $92.5 per share, on heavier‑than‑usual volume of around 12.7 million shares, versus an average near 8.9 million. MarketBeat+1 That marked another down day in an early‑December pullback that has left BSX trading at the bottom of its 50‑day range and about 15% below its 52‑week high of $109.50, set in September. MarketBeat+1 After the bell, extended trading in BSX was quiet, with the stock hovering in a tight band around

December 3, 2025 – Market close snapshot and latest news for Boston Scientific Corporation (NYSE: BSX). Boston Scientific Corporation stock remains a closely watched name in large‑cap medical technology as 2025 winds down. On December 3, 2025, the BSX share price is hovering just below the psychological $100 mark, while new headlines about insider selling, fresh European device approvals and updated analyst targets shape the near‑term story for the stock. Yahoo Finance Below is a detailed look at how Boston Scientific stock is trading today, the most important news items from December 2–3, and what Wall Street now expects for